The FLT3-ITD mutation was found in 1 of the 84 hypocellular AML patients tested (1.2%) and in 242 of the 1694 non-hypocellular AML patients tested (14.3%) (P < .001). This evidence concerns the gene FLT3 and acute myeloid leukemia.